The companies will use the AI-based platform to accelerate cancer drug discovery. Credit: sanjeri via Getty Images. AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a ...

The platform enables an understanding of the interactions between T cell receptors and their corresponding antigenic epitopes. Credit: THICHA SATAPITANON / Shutterstock. Repertoire Immune Medicines ...

In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against other firms that topped Wednesday’s trading. Wall Street’s major indices rebounded anew on ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

Tempus AI (Nasdaq: TEM) and D-Wave Quantum (NYSE: QBTS) are up by double-digit percentages today while Rigetti Computing (Nasdaq: RGTI) is enjoying a nice pop amid signs AI and the quantum ...

Tempus AI announces a multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. Tempus says the collaboration includes $200 million in data ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

Weeks ago, Tempus AI took off on news Nancy Pelosi picked up 50 of the TEM January 2026 $20 call options. It also got a boost from Cathie Wood and Ark Invest buying 445,958 shares. Fueling even ...

Investors with a lot of money to spend have taken a bullish stance on Tempus AI TEM. And retail traders should know. We noticed this today when the positions showed up on publicly available ...